ArticleCancers2023

Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.

Yeong Gyu Jeong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.